Financial Performance - The company's operating revenue for Q1 2023 was ¥119,423,435.11, a decrease of 0.85% compared to ¥120,451,245.21 in the same period last year[4] - The net profit attributable to shareholders was ¥4,024,418.08, representing a significant decline of 69.15% from ¥13,044,337.80 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥115,039.00, down 99.09% from ¥12,583,964.03 in the previous year[4] - The company’s basic and diluted earnings per share were both ¥0.03, down 72.73% from ¥0.11 in the same period last year[4] - Net profit for Q1 2023 was CNY 3,651,134.29, down 71.5% from CNY 12,776,354.19 in Q1 2022[20] - Total operating costs increased to CNY 120,171,920.93, up 10.57% from CNY 108,873,562.70 in the previous year[19] Cash Flow - The net cash flow from operating activities was -¥57,394,913.52, worsening by 56.99% compared to -¥36,560,040.95 in the same period last year[4] - The net cash flow from operating activities decreased by 56.99% to -57,394,913.52 RMB due to reduced cash received from sales and increased cash paid for purchases[14] - The company reported a net cash outflow from operating activities of CNY -57,394,913.52, compared to CNY -36,560,040.95 in Q1 2022[21] - The cash inflow from operating activities totaled CNY 120,839,809.00, down from CNY 134,908,853.94 in Q1 2022[21] - The net cash flow from investing activities increased by 125.81% to -148,163,433.78 RMB primarily due to cash used for fixed asset construction related to fundraising projects[14] - The net cash flow from investment activities was -148,163,433.78 CNY, indicating a significant outflow compared to the previous period's outflow of -65,614,398.87 CNY[22] - The total cash inflow from financing activities was 130,377,770.11 CNY, while the cash outflow was 123,527,591.55 CNY, resulting in a net cash flow of 6,850,178.56 CNY[22] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥2,076,908,041.96, a slight increase of 0.42% from ¥2,068,317,317.70 at the end of the previous year[5] - The total liabilities increased to CNY 1,092,116,167.07, compared to CNY 1,087,176,743.47 in the previous year[20] - Total current assets decreased from 1,213,731,540.24 RMB to 1,063,291,961.48 RMB, with cash and cash equivalents dropping significantly[17] - Short-term borrowings decreased from 321,630,876.40 RMB to 200,000,000.00 RMB, indicating a reduction in debt levels[17] - Long-term borrowings increased from 158,120,000.00 RMB to 288,497,770.11 RMB, suggesting a shift towards long-term financing[17] Shareholder Information - The company reported a total of 16,351 common shareholders at the end of the reporting period[14] - The top shareholder, Xi Zubin, holds 31.72% of the shares, amounting to 36,567,000 shares[14] Government Support and Other Income - The company received government subsidies amounting to ¥4,600,062.17 during the reporting period[6] - The company recorded an investment income of CNY 92,910.39, compared to a loss of CNY 2,053.21 in the previous year[20] Research and Development - R&D expenses rose to CNY 10,545,515.62, an increase of 18.6% from CNY 8,891,743.44 in the same period last year[20] Other Observations - The report was not audited, which may affect the reliability of the financial data presented[23] - The company experienced a foreign exchange impact of 18,738.78 CNY on cash and cash equivalents[22] - The cash outflow for the acquisition of fixed assets and intangible assets was 133,205,299.96 CNY, significantly higher than the previous period[22] - The company has not disclosed any new product developments or market expansion strategies in the provided report[22]
共同药业(300966) - 2023 Q1 - 季度财报